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Abstract: 
Objective.  The study of the community of microorganisms (the microbiota) 
in the lower airways in children is restricted to opportunistic sampling in 
children undergoing elective general anaesthetic. Here we tested the 
hypothesis that induced sputum is a valid alternative to directly sampling 
the lower airways to study lower airway microbiota.    
Methods.  Children scheduled for elective operations were recruited. Pre-
operatively a sample of induced sputum was obtained.  After anaesthesia 
was induced, a bronchial brushing and swabs of the upper respiratory tract 
were obtained.  Bacterial community analysis was performed by 
amplification of the V3-V4 16S rRNA gene region.  
Results.  Twenty children were recruited, mean age 10.7 years.  Induced 
sputum samples were obtained from 12 children, bronchial brushing from 
14 and nasal, mouth and throat samples in 15,  16 and  17 children. The 
profile of bacterial communities was similar in the mouth, throat and 
sputum samples with the nose and bronchial samples being different. 
Actinobacteria species dominated the nose and mouth, Fusobacteria were 
the dominant species in the throat and sputum whilst Proteobacteria 
species dominated in bronchial samples.  Forty-one percent of detected 
bacteria in bronchial samples were unclassified.  Bacterial communities 
from the mouth, throat and induced sputum were tightly clustered and 
were distinct from nose and those found in bronchial communities.  
Conclusions.  Induced sputum may not be a valid surrogate for microbiome 
assessment of the lower airways in all individuals. Many bacteria in 
bronchial samples were not recognised by standard testing, suggesting 
that our understanding of the lower airway microbiota in children remains 
rudimentary.  
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ABSTRACT  
Objective.  The study of the community of microorganisms (the microbiota) in the lower 
airways in children is restricted to opportunistic sampling in children undergoing elective 
general anaesthetic. Here we tested the hypothesis that induced sputum is a valid 
alternative to directly sampling the lower airways to study lower airway microbiota.   
Methods.  Children scheduled for elective operations were recruited. Pre-operatively a 
sample of induced sputum was obtained.  After anaesthesia was induced, a bronchial 
brushing and swabs of the upper respiratory tract were obtained.  Bacterial community 
analysis was performed by amplification of the V3-V4 16S rRNA gene region.  
Results.  Twenty children were recruited, mean age 10.7 years.  Induced sputum samples 
were obtained from 12 children, bronchial brushing from 14 and nasal, mouth and throat 
samples in 15,  16 and  17 children. The profile of bacterial communities was similar in the 
mouth, throat and sputum samples with the nose and bronchial samples being different. 
Actinobacteria species dominated the nose and mouth, Fusobacteria were the dominant 
species in the throat and sputum whilst Proteobacteria species dominated in bronchial 
samples.  Forty-one percent of detected bacteria in bronchial samples were unclassified.  
Bacterial communities from the mouth, throat and induced sputum were tightly clustered 
and were distinct from nose and those found in bronchial communities. 
Conclusions.  Induced sputum may not be a valid surrogate for microbiome assessment of 
the lower airways in all individuals. Many bacteria in bronchial samples were not recognised 
by standard testing, suggesting that our understanding of the lower airway microbiota in 
children remains rudimentary.   
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INTRODUCTION 
The lower airways were traditionally considered sterile in healthy individuals, and this 
paradigm was based on observations that standard microbiology culture from samples 
collected from healthy individuals yielded no pathogens
1
.  The advent of polymerase chain 
reaction (PCR) testing for bacterial DNA has now identified communities of bacteria in lower 
airway secretions from healthy individuals
2,3
.  The relevance of bacteria in airway microbiota 
to respiratory symptoms is unclear, but there is evidence suggesting that the microbiota 
may be relevant to influence respiratory exacerbations
2,4
 or even to the aetiology of chronic 
respiratory conditions such as asthma
5
.  Exacerbations of chronic conditions such as cystic 
fibrosis (CF) and chronic obstructive pulmonary disease are linked to a change
2
 (termed 
“airway dysbiosis”) or reduction
4
 in the dominant bacterial species in the microbiota.  In 
young infants, those carrying Haemophilus influenzae or Moraxella catarrhalis in the 
hypopharynx were more likely to have asthma symptoms at three years of age
5
.   
 
A major challenge to studying the lower airway microbiota is obtaining samples without 
contamination from the upper airways
3
, and it is known that the microbiota in the naso- and 
oropharynx differ from that in the bronchus in adults and children
6–8
.  Three papers have 
used bronchoscopic sampling to compare the upper and lower airway microbiome in 
children and whilst there are similarities in the dominant phyla identified in some studies, 
there are differences in genera identified and also in the clustering of bacterial 
communities
6–8
.  The characteristics of the lower airway microbiome may also vary between 
individuals depending on their asthma status
6
 and using a nasal or oral approach to the 
lower airways
8
. . Two studies in young people with CF have compared the microbiota in 
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induced sputum and oropharyngeal swabs
9,10
, and both concluded that a throat swab 
sample may be a valid surrogate for sputum for microbiota analysis.  Induced sputum is a 
non-invasive alternative to direct bronchial sampling, and is used in the clinical management 
of tuberculosis and CF in children and also in research.  The study of the lower airway 
microbiome would be considerably easier if induced sputum was a valid surrogate of 
bronchial fluid.  The aim of the current study was to collect induced sputum and samples 
from the bronchus, nose, throat and mouth in children and undertake a comprehensive 
assessment of upper and lower airway microbiota in children.  Our hypothesis was that 
induced sputum is a valid alternative to directly sampling the lower airways to study lower 
airway microbiota.      
 
METHODS 
Study design 
Children aged 5-16 years and scheduled for elective ear nose and throat operations at Royal 
Aberdeen Children's Hospital between January and June 2015 were invited to take part. All 
children were scheduled for tonsillectomy and some also had grommets inserted. These 
operations require endotracheal intubation, which allows sampling of the lower airways 
without contamination by the upper airways.  Children younger than 5 years were excluded 
since they were unlikely to provide a sample of induced sputum.  Other exclusion criteria 
included receipt of antibiotics within the last month and CF.  In the hours before the 
operation (when the child was fasted), children took part in an assessment which included 
completion of a questionnaire, height and weight measurement, spirometry (in accordance 
with international guidelines
11
) and induction of sputum using 4% and if required 5% saline 
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as previously described
12
.  An adequate quality sputum sample was defined as the presence 
of a white sputum plug on a visual inspection; samples were not sufficiently large enough to 
allow for cell count analysis.  Immediately after anaesthesia was induced and the 
endotracheal tube in situ, a sterile 2.7 mm interdental brush (Dento Care Professional, 
London UK) was used to collect a sample of nasal secretions and a separate brush 
interdental brush was gently brushed on the buccal surface of the mouth to collect oral 
secretions.  A standard bacterial swab (Transwab, Medical Wire Equipment, Corsham, UK) 
was used to obtain a sample of pharyngeal secretions under direct inspection.  Finally, a 
bronchoscopy cytology brush (10-mm disposable cytology brush, BC 202D-2010, Olympus, 
Southend-on-Sea, Essex, UK) was passed down the endotracheal tube until resistance was 
met and then rotated and withdrawn to obtain “blind” bronchial samples.  Blood was taken 
for serum total IgE assay. The study was approved by the North of Scotland Research Ethics 
Committee (13/NS/0144), written parental consent was obtained and verbal assent was 
obtained from all participants.    
 
DNA extraction and sequencing  
The bacterial community analysis was carried out as described previously
13
 with some 
modification as detailed below. Briefly, samples taken from the nose, mouth, throat, 
sputum and bronchial brushing were frozen at −80°C prior to analysis.  Samples were then 
transported from Aberdeen to Dundee for processing. Upon arrival the sample had thawed 
and were suspended in phosphate buffer saline where genomic DNA was extracted and 
purified using the DNA/RNA All Prep kit
14
 (Qiagen) and stored according to manufacturer’s 
instructions. Standard protocol, 16S Metagenomic Sequencing Library Preparation Guide 
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(Illumina), was followed to prepare sequencing libraries targeting the variable V3 and V4 
regions of the 16S rRNA gene and paired-end sequencing was performed on the MiSeq 
System (Illumina). We followed sampling and controls procedures described by the Earlham 
Institute 
(http://www.earlham.ac.uk/sites/default/files/docs/Genomic%20Services/Sample%20Guide
lines%20Aug17.pdf) and Illumina 
(https://support.illumina.com/documents/documentation/chemistry_documentation/16s/1
6s-metagenomic-library-prep-guide-15044223-b.pdf 
which are designed to minimize the risk for contamination.  Quality controls and sequencing 
were performed at Earlham Institute (Norwich, UK).  
Data and Statistical analysis  
Bioinformatics analyses on raw data was performed using the Biomedical Genomics 
Workbench version 4.0 (Qiagen) equipped with the Microbial Genomics Module version 2.0 
(Qiagen) plugin. Sequences were imported and processed for optional merge paired reads, 
adapter trimming, fixed length trimming and then the sequences were filtered based on the 
number of reads to obtain sequences that are comparable in length and coverage for 
clustering. Quality and chimera filtering were performed using the recommended 
programme parameters [for complete details see www.qiagenbioinformatics.com]. Samples 
with low coverage were removed from further analysis. Operational Taxonomic Units (OTU) 
clustering and taxonomic assignment were done using Greengenes v13_5 (97%) as 
reference. New OTUs were indicated when similarity percentage was lower than 80% with 
minimum occurrence of 5 reads. Low abundant OTUs were discarded from further analyses 
(minimum combined abundance was set at 10). Summary of processed sequence data is 
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described in Table S1.  MUSCLE was used for OTUs alignment in order to reconstruct a 
maximum likelihood phylogeny with neighbor joining as construction method and Jukes 
Cantor as nucleotide substitution model. We compared community structures and diversity 
across patient cohorts to determine if inter-cohort differences in structure were seen. To 
achieve this a rarefaction sampling analysis was carried out using a standard methodology
15
. 
In order to minimise the risk for contamination, we sought to identify a high (i.e. 
conservative) number of sequences required to characterise bacteria from the samples.  In 
the absence of a standard international stringency cut off the default settings in the 
workbench software (Qiagen) were applied; the default settings filters out many reads and 
generates fewer unassigned reads and is therefore highly stringent. These adjustments were 
assessed by analyzing a previously characterized mock community to confirm that the data 
handling was consistent with other studies (sequencing files of the project: 
ERP021973,https://www.ebi.ac.uk/metagenomics/projects/ERP021973/samples/ERS15889
32). Data generated in the study was assessed using the Qiagen software and also applied to 
EBI Metagenomics analysis pipeline V3.0 to verify results (acknowledging that fewer reads 
would remain in the analysis with Qiagen).    The findings in the controls were taken into 
account during the analysis.   Alpha diversity was calculated using number of OTUs. Beta 
diversity was obtained using D_0.5 UniFrac and represented as Principal Coordinate Analysis 
(PCoA). Robustness analysis was performed using PERMANOVA with UniFrac distances. All 
sequencing data have been deposited in NCBI Sequence Read Archive (SRA) database under 
the follow BioProject ID:  PRJNA388557 
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RESULTS 
Study Subjects 
Twenty patients recruited of which 8 were boys, 7 with diagnosed asthma and the mean 
(standard deviation) age was 10.7 (2.8) years. Descriptives of the children recruited are 
given in Table 1.  Induced sputum was obtained from 12 children and samples of fluid from 
bronchus, throat mouth and nose were obtained in all children.  Three control samples were 
collected.   
Sample quality control 
A total of 11,750,879 PCR reads were were analysed, and 606,227 high quality reads were 
obtained.  The resulting OTU table contained 1053 OTUs, where 532 OTUs were assigned 
based on the Greengenes v13_5 (clustered at 97% similarity), and 521 OTUs were novel (see 
Table S1).  These processing criteria allowed data from 74 samples from patients for further 
analyses.  Of these 15 were from the nose, 16 from mouth, 17 from throat, 12 from sputum 
and 14 from bronchial samples (Table S2).  Samples from all five sites were available in six 
children. The median read counts for the five sites were as follows: bronchus 4438; mouth 
4400; throat 4868; nose 8927; and sputum 11250.  The results from the mock community 
analysis using Qiagen and EBI Metagenomics analysis pipelines were highly consistent.  
However Qiagen software assigned phyla for all samples whereas the EBI Metagenomics did 
not assign phyla in 15% of samples (see Table S3).    
 
Bacterial abundance 
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The relative bacterial abundance in each sample cohort is presented in Figure 1. The overall 
profile of bacterial communities was largely similar in the mouth, throat and sputum 
samples with the nose and bronchial being different. All sample cohorts contained five 
major bacterial phyla: Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria and 
Proteobacteria. The three most abundant phyla of bacteria observed by analysis in nose, 
mouth, throat, bronchial and sputum were Actinobacteria, Fusobacteria and Bacteroidetes 
(seen in Figure 1).  Actinobacteria dominated in the nose (73% of all total species) and 
mouth (37%) samples, Fusobacteria dominated in throat (31%) and sputum (38%) samples 
and Proteobacteria were dominant in bronchial samples (34%).  Both nasal and bronchial 
samples had more unclassified OTUs (12% and 41% respectively) than other samples. The 
relative abundance of each individual sample is shown in Figure 2.  Figure S1 presents the 
phylogenetic tree of the microbial community in all analysed samples. In two of the control 
samples there was no identifiable bacteria DNA signal however some DNA signal was 
detected in the one of the three control and this was taken into account during analysis (See 
Figure 2).    
Comparison between complete community structures within samples from different sites 
The rarefaction analysis suggested that 2000 sequences would be sufficient for 
characterizing the majority of bacteria present in these communities. The numbers of reads 
were lowest in bacterial communities from mouth and bronchus (Figure 3; Table S2). A 
comparison of individual bacterial communities, using PERMANOVA principal coordinate 
analysis (PCoA), showed a distinct clustering by sample cohorts based roughly on where the 
sample was taken from. Bacterial communities in samples from the mouth, throat and 
induced sputum were tightly clustered together (padj=1) and were distinct from those of 
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the nose and bronchus (padj<0.001), which independently clustered (Figure 4; Table 2); 
these clustering results were seen when children with asthma and without asthma were 
considered separately (Table S4), Table S5 demonstrates that clustering of bacterial 
communities was not evident between sites among subgroups stratified by asthma/not 
asthma or atopy/not atopy. 
The bacterial communities in the five sites sampled did not differ between the children with 
and without asthma; there was evidence of some differences in bacterial abundance and 
diversity between groups (see supplement Figure S2). A comparison of the abundant phyla 
of bacteria identified in bronchial samples taken from asthma and non-asthma patients 
showed the profiles were similar, but the abundance of a signal for phyla was different (but 
did not reach significance).  In bronchial samples from asthma patients, the abundant phyla 
identified was Proteobacteria while those samples taken from non-asthma patients showed 
a greater abundance for Fusobacteria.   
 
DISCUSSION 
This study was designed to determine whether induced sputum is a valid alternative to 
directly sampling of the lower airways to study airway microbiota in children.  The main 
finding was that the characteristics of the microbiota in induced sputum and in bronchial 
samples were different.  A second finding was that a minority of bacterial DNA in bronchial 
samples was unclassified.  In two individuals (P12 and P16, see Figure 2) the proportion of 
phyla identified from the bronchial sample was similar to the sputum sample but for the 
remainder of participants there were clear differences in the proportions of different phyla 
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from bronchial and sputum samples. Together these findings suggest that induced sputum is 
not a valid surrogate for direct bronchial sampling to study the lower airway microbiota in 
all children, but that there is still a pressing need to better understand the lower airway 
microbiota in children.  Opportunistic bronchial sampling under clinically-indicated general 
anaesthetic should remain the gold standard for studying lower airway microbiome in 
children.  
To our knowledge there are only three studies which have compared the microbiota of 
upper and lower airway secretions in healthy children or children with asthma
6–8
.  A study 
where the majority of recruits were adults showed that the bacterial community in the 
oropharynx and bronchus were similar in healthy individuals
6
.  One solely paediatric study 
found very little overlap between the microbiota of the oropharynx and lower airways
7
 
whilst a second paediatric study found similar predominant phyla in upper and lower airway 
samples but different genera8.  Both paediatric studies found significant differences in the 
clustering of bacterial communities in the upper and lower airways
7,8
. The dominant phyla in 
bronchial  samples is not consistent between studies but there is consistency for upper 
airway samples.  For example, the microbiota of the upper airways is predominated by 
bacteria from the Firmicutes (e.g. Staphylcoccus and Streptococcus) and the Actinobacteria 
phyla (e.g. Corynebacteria) in our study  and three others 
6–8
.  In contrast and in bronchial 
samples, bacterial species within the Proteobacteria phylum (including Moraxella and 
Haemophilus) predominated in our study and one other
7
 but Firmicutes dominated in a 
third study8., Differences in lower airway microbiome between studies may be due to 
different sampling methods8 and treatment with current or recent antibiotics
7,8
. Our results, 
where we find no differences between the microbiome of induced sputum and throat swab, 
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are also consistent with previous studies which suggested that a throat swab may be a 
useful surrogate of induced sputum in young children with CF
9,10
. As our study did not 
include children with CF we cannot comment on the validity of induced sputum as an index 
of lower airway infection in this specific clinical setting.  The consistency of our results with 
previous studies assures us that our findings are valid, despite the relatively small sample 
size. 
Our study findings were based on samples taken from a group of children who were well.  
Recent work has given insight into the relationship between airway microbiota in the upper 
airways of children with acute infection, with results which differ from the present study.  
For example there is evidence that in the context of acute upper and lower respiratory tract 
infection, different bacterial species predominate in the nasopharynx (e.g. Proteobacteria 
and Firmicutes which contrast with Actinobacteria and Fusobacteria in our study)
15
. The 
characteristics of the nasopharyngeal microbiota also change during the course of acute 
otitis media infection
16
.     
Our study design minimised the risk of false positive results arising from contamination and 
from samples containing low DNA yields.  There is no consensus on the number of control 
samples which should be collected for microbiome studies, and two of the three controls we 
collected contained no bacterial DNA and a third contained only bacteria with a very 
different profile of phyla compared to the samples from study subjects.  We set out to have 
a high threshold for reads (>2000) and this filtered out samples with low DNA yields.  
Another source of potential contamination comes from reagents used to analyse the 
samples and this risk was minimised by taking standard precautions were taken and by 
including control samples in the analysis.  Whilst we cannot exclude the possibility that 
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some contamination may have occurred, our robust methodology and the consistency of 
our findings with previous studies assure us that any contamination has not substantially 
affected our findings. 
Finding a small proportion of unassigned bacterial DNA in the nose and bronchial samples 
was unexpected and worthy of further investigation.  The presence of “unclassified 
bacteria” has been described in nasopharyngeal samples from children
7
, but not in bronchial 
samples.  We have carefully reviewed the unassigned sequences and removed human DNA 
sequences, and we therefore believe that there are a number of bacteria in the respiratory 
tract which are not identified by standard microbiota methodologies currently used.   We 
analysed data from a mock community (a “positive control”) and this demonstrated that the 
Qiagen software used for analysis of our samples was able to detect bacteria in similar 
proportions to another software “pipeline”. The Qiagen software identified all phyla 
whereas the alternative software could not assign 15% of bacterial DNA and this may be 
explained by the higher stringency set for the Qiagen software. There is not standard for 
stringency but these results suggest that although the higher stringency reduces the number 
of reads included in the analysis, the results are highly comparable to other methods and 
possibly less affected by potential contaminants.  Our data are publicly available and 
colleagues are welcome to apply different stringencies to our data.   
There are a number of settings where upper airway samples have been shown to be valid 
surrogates of lower airway samples for the clinical diagnosis of infective and non-infective 
conditions.  Viral aetiology in bronchiolitis (a lower respiratory tract infection) can be 
established by nasopharyngeal aspirate
16
 and the nasal mucosa is used for diagnosis of 
primary ciliary dyskinesia
17
 and (in some situations) CF
18
.   In the research setting, sampling 
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from the upper airways has been validated as a surrogate for lower airway sampling
19,20
.  
However, we demonstrated that the microbiota of the nose was distinct to mouth and 
bronchus in most individuals and our results indicating that the microbiota of the upper 
airway is probably not a valid surrogate of lower airway microbiota in children.  Previous 
papers have suggested that with regards to lower airway samples, upper airway samples are 
“imperfect but reliable”
7
 and “both similar and different”
8
and overall, our work finds more 
evidence for the upper airways samples being “imperfect and different” to lower airway 
samples and not “reliable and similar”. . 
The novelty of our study is that we demonstrate how the microbiota of induced sputum 
differs from bronchial samples and very closely matches the microbiota of mouth and 
throat, most likely due to contamination of lower airway secretions as they pass through the 
oropharynx, including sputum which is commonly mixed with expectorant.   Our findings are 
consistent with a study of 78 children (mean age 2 years, almost half having received recent 
antibiotic treatment) which also describes differences in the microbiota between nose and 
mouth and between mouth and bronchial fluid
7
.  Consistent with our findings, a study of 
adults and children (mean age 11 years) reports Actinobacteria being the predominant 
phyla in the nose but being almost absent from the oropharynx and bronchus. A different 
pattern is shown for Proteobacteria which are increasing from nose through to oropharynx 
and bronchus
6
.  The apparent presence of different dominant bacterial communities in the 
upper and lower airways raises the question “where do bacteria in the lower airways 
originate?” 
In children the lower airways are in direct communication with and adjacent to the 
oropharynx but there are several  mechanisms that  may lead to the establishment of 
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different bacterial communities above and below the vocal cords.  Perhaps most obviously, 
a child’s mouth is regularly exposed to food and inedible items introduced to the oral cavity 
(including cutlery and fingers) whereas the lower airways are exposed only to inhaled 
exposures.  Micro aspiration due to laryngopharyngeal reflux is thought to occur on a 
regular basis
21
 and exposure to acid and other gastric contents (including bacteria) may 
affect the microbiota of the lower airways but not the oropharynx. There are differences in 
the innate defences of the upper and lower airways which may also explain differences in 
their respective microbiota, for example lactoferrin concentrations are twice as high in the 
lower airways relative to upper airways
22
 whereas nitric oxide concentrations (known to 
have antimicrobial properties
23
) are typically one hundred times higher in the upper 
airways. 
Our study was not designed to relate microbiota to clinical phenotypic data collected, for 
example asthma or atopy. However, in light of recent studies examining these parameters in 
children with asthma
6,7
 we made the best use of the data available, even with the limited 
number we had at our disposal.  When examined the possible relationship between the 
bacteria present in children with and without asthma or atopy, we found no statistically 
differences between the bacteria when the samples were examined as a whole group or as 
specific sample region cohorts (nose, mouth, throat, bronchial and sputum samples), Figure 
S2 and Table S3.  A descriptive analysis of the bronchial samples collected found 
Protoebacteria to be the dominant species and this is consistent with Hilty et al
6
.  
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There are some limitations to our study.  First, the number of participants was relatively 
small.  Second, induced sputum was not obtained in all participants and not all samples met 
our quality control criteria for bacterial DNA analysis and this resulted in missing data for 
some individuals.  Third, as has been reported in other sputum microbiome studies
6,7
, we 
were not able to perform cell counts on the sputum pellet to determine the presence of 
neutrophils and absence of squamous epithelial cells. Finally, we did not prospectively 
calculate the DNA yield from samples although the consistency of our results with the small 
number of published studies
6,7
, the consistency of results using both the Qiagen and EBI 
Metagenomics pipelines and the comparable results from mock communities assure is that 
low DNA yield has not altered the results.  
In summary, we report that neither induced sputum nor swabs from nose or mouth give an 
accurate indication of the bronchial microbiota in all children.  For very obvious practical 
and ethical reasons, upper airway sampling will be necessary to study airway microbiome in 
many research setting and our findings adds to the evidence describing the limitations of 
this pragmatic approach.    Our study was not designed to compare differences in the lower 
airway microbiota of children with and without asthma, and future research is required to 
supplement the little we do know about this potentially important subject.  
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FIGURE LEGENDS 
Figure 1. Relative abundances of bacterial phyla identified as operational taxonomic units 
(OTUs) from the sequence reads generated from airway samples taken from children. The 
bar chart illustrates the taxonomic composition of each cohort of samples from a particular 
site. A detailed summary of the bacteria in each sample is described in Figure 2.  
Figure 2.  Operational Taxonomic Units based relative sequence abundance of bacterial 
phyla based on 16S rRNA of all 75 samples. A detailed summary of the bacteria in each 
sample is described. On the horizontal axis, the number following P is the patient number 
and NO=nose, MO=mouth, TH=throat, SP=Sputum, BR=bronchial sample. C2=the control 
sample where bacterial DNA was detected. N/A=not applicable 
Figure 3. Alpha diversity rarefaction curves of samples based on total number of observed 
Operational Taxonomic Units.  Colour denotes different sample cohort (“nose” (NO), 
“mouth” (MO), “throat” (TH), “sputum” (SP) and “bronchial” (BR) samples). 
Figure 4. Diversity analysis demonstrating differences in the bacterial phyla community 
between samples taken from airway samples taken from asthmatic and non-asthmatic 
children.  Principal coordinate (PCo) analysis of all samples based on D_0.5 UniFrac distance. 
Colour denotes different sample cohort (“nose” (NO), “mouth” (MO), “throat” (TH), 
“sputum” (SP) and “bronchial” (BR) samples).  Y=sample from child with asthma. 
Figure S1. Phylogenetic tree of the microbial community in all analysed samples.  All 
Operational Taxonomic Units are shown in this figure. 
Figure S2.  Bacterial phyla abundance and diversity between groups. On the horizontal axis, 
the first letter “Y” indicates that the child had asthma and “N” that they did not have 
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asthma and NO=nose, MO=mouth, TH=throat, SP=Sputum, BR=bronchial sample. N/A=not 
applicable 
TABLE LEGENDS 
Table 1.  Details of the children recruited. SABA=short acting beta agonist, ICS=inhaled 
corticosteroids, LABA=long acting beta agonist 
Table 2.  PERMANOVA analysis results of testing differences in beta-diversity among 
different sample sites. 
Table S1. Summary of sequence data used for Operational Taxonomic Units (OTU) clustering 
and analysis.  The number of filtered reads and reads in OTUs doee not include the reads 
excluded by quality control 
Table S2.  List of sequence data for individual samples used for Operational Taxonomic Units 
(OTU) clustering and analysis. 
Table S3.  Comparison of results from two pipelines used to analyse data.  The Qiagen 
pipeline was used for the present study.  The EBA pipeline (full name EBI Metagenomics 
analysis pipeline V3.0) was used as a comparator 
Table S4. PERMANOVA analysis separately comparing beta-diversity among different sample 
sets for children with asthma and without asthma. 
Table S5. PERMANOVA analysis comparing beta-diversity among different sample sets. 
Atopy was defined as serum IgE >100 kU/l. 
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Figure 1. Relative abundances of bacterial phyla identified as operational taxonomic units (OTUs) from the 
sequence reads generated from airway samples taken from children. The bar chart illustrates the taxonomic 
composition of each cohort of samples from a particular site. A detailed summary of the bacteria in each 
sample is described in Figure 2.  
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Figure 2.  Operational Taxonomic Units based relative sequence abundance of bacterial phyla based on 16S 
rRNA of all 75 samples. A detailed summary of the bacteria in each sample is described. On the horizontal 
axis, the number following P is the patient number and NO=nose, MO=mouth, TH=throat, SP=Sputum, 
BR=bronchial sample. C2=the control sample where bacterial DNA was detected. N/A=not applicable  
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Figure 3. Alpha diversity rarefaction curves of samples based on total number of observed Operational 
Taxonomic Units.  Colour denotes different sample cohort (“nose” (NO), “mouth” (MO), “throat” (TH), 
“sputum” (SP) and “bronchial” (BR) samples).  
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Figure 4. Diversity analysis demonstrating differences in the bacterial phyla community between samples 
taken from airway samples taken from asthmatic and non-asthmatic children.  Principal coordinate (PCo) 
analysis of all samples based on D_0.5 UniFrac distance. Colour denotes different sample cohort (“nose” 
(NO), “mouth” (MO), “throat” (TH), “sputum” (SP) and “bronchial” (BR) samples).  Y=sample from child with 
asthma.  
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Whereas some minor issues have been addressed major issues are still not sufficiently replied to. I 
am still not convinced that one the main messages, namely that bronchial samples differ significantly 
from induced sputum, is justified by the data and therefore allows to conclude: “Induced sputum 
may not be a valid surrogate for microbiome assessment of the lower airways.”  
Before going into a deeper analysis I would like to mention that a considerable part of confusion 
comes due to erroneous labeling and numbering of the figures and tables. E.g. in my previous review 
I referred in point 4 to Fig. S2 which according to the legends was the phylogenetic tree (yet the 
Figure itself had no label) and claimed the absence of Streptococci and Haemophilus. In the reply the 
authors now refer to bar graphs that of course only show phyla. This is not a reply to my question. 
Moreover the current manuscript is still superficial in preparation: Fig. S2 as labeled in the legends 
(“Figure S2. Bacterial phyla abundance and diversity between groups”) is sjown as Fig. S3 on p.30. In 
Fig. 1 the legend gives a note “A detailed summary of the bacteria in each sample is described in 
Figure S1.” but this is now Fig. 2. Therefore I now always refer to the page number indicated at the 
top of the pdf file. 
 
Our response: We apologise for any confusion caused. On the advice of the reviewer we moved one 
figure from the supplement to the main paper.  Therefore the numbering of figures in the 
supplement changed between the first and the revised manuscript and we failed to capture all of 
these changes. There are four specific points raised by the reviewer here: 
1. Incorrect legend for Figure 1 - We have corrected the error in the legend for Figure 1 (i.e 
changed “Figure S1” to “Figure 2”). 
2. Reply to point 4 in initial review - The reviewer did not refer to Figure  S2 in point 4 of their 
previous review (they did refer to this in point 7). We do not know which question the 
reviewer invites us to reply to.  
3. No label for phylogenetic tree in supplement - We have inserted a label for Figure S1. 
4. Figure S2 labelled as Figure S3 - We have corrected this error. 
 
Severe technical shortcomings remain and these are again outlined: 
1. It is not sufficiently clarified how the analysis results in such an enormous loss of reads: 
Previously of 21.5 million reads only 400,493 were analyses, now it reads that from 11.7 million reads 
606,227 could be analysed. Why were now fewer reads available? Why are less than 10% analysed? 
This is a very unusual yield for 16S sequencing. The authors refer to “high stringency” and p.7 for 
further explanations in their response but this stringency is nowhere explained. I am afraid that 
important information is missed. 
 
Our response: There are actually now more reads and a smaller proportion of “lost” reads included 
in the analysis reported in the revised manuscript (606,227 compared to 400,493). There is no 
standard for stringency and, as the reviewer will be aware, the advantage of a higher cut off reduces 
the potential for “false positive” findings. In this study, we used the default settings in the 
workbench software (Qiagen). This has a very “high stringency” cut off which means that a lot of 
reads are removed. Our data are publicly available and colleagues can apply different stringency 
thresholds to our data. We have expanded the text on page 7 to explain our approach to stringency 
which explains the threshold used. Finally (as suggested by the reviewer) we have used a mock 
community to replicate data from our pipeline using second pipeline which applied a different 
stringency; this last analysis indicates that our stringency has not affected the diversity of 
microbiome detected but has increased the accuracy of detection (data now included in Table S2). 
  
2. On “p.29 of 62” the authors again show the phylogenetic tree that should show “all analysed 
samples”. In this tree I do neither see the genus Streptococcus which should be found in all healthy 
individuals at least in the mouth and throat or Haemophilus which has been reported as a typical 
proteobacterium in asthma patients. I come to the same conclusion as in (1.) that important 
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information might be missing. That is why I requested to analyze a defined mock community but the 
authors refuse to do so. I do not see why this should not be possible even if the study was closed.  
 
Our response: This phylogenetic tree shows details of phyla and does not provide details of species. 
Therefore species such as Streptococcus and Haemophilus are not shown.  The analysis of mock 
community indicates that our pipeline more sensitive than a second pipeline and that important 
information is not missing. We have provided more labels on the phylogenetic tree identifying more 
phyla. 
 
 
3. I previously stated that I am afraid that in bronchial samples the bacterial yield might have 
been low and therefore prone to contamination. Indeed the new Fig. 2 clearly shows that in the one 
control sample proteobacteria were brought in. I am afraid that in samples with known low yield 
(bronchial washing from healthy individuals) this might induce an error as previously reported (Salter 
et al. BMC Biology 2014, 12:87). I therefore requested to do an analysis of bacterial load (e.g. 
quantitative 16S PCR). The authors now refer me to Table S2 but this is entirely misleading. “Number 
of reads” has nothing to do with the original bacterial load. During the pipeline of mixing and 
barcoding for the sequencing process typically equal amounts of PCR products are taken. After the 
sequencing the number of reads only reflects variation in the sequencing and does not relate to the 
original bacterial load. Without seeing true data on bacterial load the issue of contamination cannot 
be discussed in sufficient depth. 
 
Our response: We believe that the mock community analysis described previously addresses the 
issue of low DNA yield in bronchial samples (see Table S2). There was not sufficient sample volume 
to determine the bacterial yield. The mock community analysis and consistency with published data 
assure us that low bacterial load in bronchial samples has not substantially affected our results. We 
have added text acknowledging that we did not calculate DNA yield. We have also added a very 
recently published paper which also finds different clustering of bacterial communities in the upper 
and lower airways.  
 
4. From Table S2 it is visible that for the bronchial samples a number of samples had to be 
excluded because that did not give enough reads. I am afraid that the majority were from healthy 
children whereas those from asthmatic were analysed. The latter are known to have a higher 
Proteobacteria load. Therefore it is mandatory, to show the disease status in Fig. 2. Moreover, I 
would like to see separate PERMANOVAs for diseased and healthy children with respect to 
differences between sputa and bronchial washings. This is not covered so far by any of the analysis 
and from the Fig. on “p. 30 of 62” (mislabeled as S3) it becomes clear that the difference between 
NBR and NSP is much less as compared to YBR vs. YSP. I do NOT want to make a conclusion on 
asthma patients but I state that the mixing of healthy and diseased people in on population might be 
a significant problem. This might be also visible when Fig. 2 would be labeled with the disease status: 
From a look at Fig. 2 it seems that at least 3-4 samples are much more similar to the throat/sputum. 
The conclusion of difference between BR and SP is mostly based on the unassigned sequences and for 
those the data do not sufficiently exclude a contamination issue (see my comment 3). 
 
Our response: The reviewer makes a number of points here: 
• Samples need labelling by asthma status in figure 2. We have done this 
• Separate PERMANOVA for children with and without asthma.  We have done this (table S4) 
• Difference between BR and SP is mostly based on unassigned sequences.  We have now 
removed unassigned sequences from this figure and the majority of bronchial samples are 
predominantly the light blue colour corresponding to Proteobacteriae whereas the sputum 
samples have very few Proteobacteriae seen but are dominated by Fusobacteria and 
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Bacteroidites.  We do acknowledge that two bronchial samples (P12BR and P16 BR) have 
few Proteobacteriae and have a similar pattern to their corresponding sputum sample.  
When all patients are considered, there are significant differences between bronchial and 
sputum samples but we have modified the conclusions to acknowledge that in a minority 
sputum samples may be a valid index of bronchial samples.  
 
5. Technically it remains unclear why in Fig. 1 unassigned sequences are shown but in Fig. 2 
excluded. Moreover, on visual inspection there seems to be a discrepancy between proteobacteria 
abundance in Fig. 2 for all BR samples (for many samples >50%) as compared to Fig. 1 (20%). How 
has the data in Fig. 1 been calculated (mean?).  All in all the data do not sufficiently justify the main 
conclusion. 
 
Our response: We have revised Figure 1 and removed the unassigned phyla. The reviewer is correct 
and data in Figure 1 are mean values.  The proportion of proteobacteria in figure 2 is certainly >50% 
for most individuals but this figure shows how two individuals (P12BR and p16BR) have very few 
proteobacteria and results from these two individuals reduce the mean proportion of proteobacteria 
to the value represented in Figure 1. We have amended the main conclusion (see point 4 above). 
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ABSTRACT  
Objective.  The study of the community of microorganisms (the microbiota) in the lower 
airways in children is restricted to opportunistic sampling in children undergoing elective 
general anaesthetic. Here we tested the hypothesis that induced sputum is a valid 
alternative to directly sampling the lower airways to study lower airway microbiota.   
Methods.  Children scheduled for elective operations were recruited. Pre-operatively a 
sample of induced sputum was obtained.  After anaesthesia was induced, a bronchial 
brushing and swabs of the upper respiratory tract were obtained.  Bacterial community 
analysis was performed by amplification of the V3-V4 16S rRNA gene region.  
Results.  Twenty children were recruited, mean age 10.7 years.  Induced sputum sSamples 
were obtained from induced sputum in 12 children, bronchial brushing fromin 14 and , 
naosal, mouth and throat samples e in 15, mouth in 16 and throat in 17 children. The profile 
of bacterial communities was similar in the mouth, throat and sputum samples with the 
nose and bronchial samples being different. Actinobacteria species dominated the nose and 
mouth, Fusobacteria were the dominant species in the throat and sputum whilst 
Proteobacteria species dominated in bronchial samples.  Forty-one percent of detected 
bacteria in bronchial samples were unclassified.  Bacterial communities from the mouth, 
throat and induced sputum were tightly clustered and were distinct from nose and those 
found in bronchial communities. 
Conclusions.  Induced sputum may not be a valid surrogate for microbiome assessment of 
the lower airways in all individuals. A large minority ofMany bacteria in bronchial samples 
were not recognised by standard testing, suggesting that our understanding of the lower 
airway microbiota in children remains rudimentary.   
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INTRODUCTION 
The lower airways were traditionally considered sterile in healthy individuals, and this 
paradigm was based on observations that standard microbiology culture from samples 
collected from healthy individuals yielded no pathogens
1
.  The advent of polymerase chain 
reaction (PCR) testing for bacterial DNA has now identified communities of bacteria in lower 
airway secretions from healthy individuals
2,3
.  The relevance of bacteria in airway microbiota 
to respiratory symptoms is unclear, but there is evidence suggesting that the microbiota 
may be relevant to influence respiratory exacerbations
2,4
 or even to the aetiology of chronic 
respiratory conditions such as asthma
5
.  Exacerbations of chronic conditions such as cystic 
fibrosis (CF) and chronic obstructive pulmonary disease are linked to a change
2
 (termed 
“airway dysbiosis”) or reduction
4
 in the dominant bacterial species in the microbiota.  In 
young infants, those carrying Haemophilus influenzae or Moraxella catarrhalis in the 
hypopharynx were more likely to have asthma symptoms at three years of age
5
.   
 
A major challenge to studying the lower airway microbiota is obtaining samples without 
contamination from the upper airways
3
, and it is known that the microbiota in the naso- and 
oropharynx differ from that in the bronchus in adults and children
6–8
.  Threewo papers have 
used bronchoscopic sampling to compare describe the upper and lower airway microbiome 
in children and  whilst there are similarities in the dominant phyla identified in some studies, 
there are differences in genera identified and also in the clustering of bacterial 
communities
6–8
.  The characteristics of the lower airway microbiome may also vary between 
individuals depending on their asthma status
6
 and using a nasal or oral approach to the 
lower airways
8
. reported a greater abundance of Proteobacteria species in those with 
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asthma compared to controls
6,7
. Two studies in young people with CF have compared the 
microbiota in induced sputum and oropharyngeal swabs
9,10
, and both concluded that a 
throat swab sample may be a valid surrogate for sputum for microbiota analysis.  Induced 
sputum is a non-invasive alternative to direct bronchial sampling, and is used in the clinical 
management of tuberculosis and CF in children and also in research.  The study of the lower 
airway microbiome would be considerably easier if induced sputum was a valid surrogate of 
bronchial fluid.  The aim of the current study was to collect induced sputum and samples 
from the bronchus, nose, throat and mouth in children and undertake a comprehensive 
assessment of upper and lower airway microbiota in children.  Our hypothesis was that 
induced sputum is a valid alternative to directly sampling the lower airways to study lower 
airway microbiota.      
 
METHODS 
Study design 
Children aged 5-16 years and scheduled for elective ear nose and throat operations at Royal 
Aberdeen Children's Hospital between January and June 2015 were invited to take part. All 
children were scheduled for tonsillectomy and some also had grommets inserted. These 
operations require endotracheal intubation, which allows sampling of the lower airways 
without contamination by the upper airways.  Children younger than 5 years were excluded 
since they were unlikely to provide a sample of induced sputum.  Other exclusion criteria 
included receipt of antibiotics within the last month and CF.  In the hours before the 
operation (when the child was fasted), children took part in an assessment which included 
completion of a questionnaire, height and weight measurement, spirometry (in accordance 
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with international guidelines
11
) and induction of sputum using 4% and if required 5% saline 
as previously described
12
.  An adequate quality sputum sample was defined as the presence 
of a white sputum plug on a visual inspection; samples were not sufficiently large enough to 
allow for cell count analysis.  Immediately after anaesthesia was induced and the 
endotracheal tube in situ, a sterile 2.7 mm interdental brush (Dento Care Professional, 
London UK) was used to collect a sample of nasal secretions and a separate brush 
interdental brush was gently brushed on the buccal surface of the mouth to collect oral 
secretions.  A standard bacterial swab (Transwab, Medical Wire Equipment, Corsham, UK) 
was used to obtain a sample of pharyngeal secretions under direct inspection.  Finally, a 
bronchoscopy cytology brush (10-mm disposable cytology brush, BC 202D-2010, Olympus, 
Southend-on-Sea, Essex, UK) was passed down the endotracheal tube until resistance was 
met and then rotated and withdrawn to obtain “blind” bronchial samples.  Blood was taken 
for serum total IgE assay. The study was approved by the North of Scotland Research Ethics 
Committee (13/NS/0144), written parental consent was obtained and verbal assent was 
obtained from all participants.    
 
DNA extraction and sequencing  
The bacterial community analysis was carried out as described previously
13
 with some 
modification as detailed below. Briefly, samples taken from the nose, mouth, throat, 
sputum and bronchial brushing were frozen at −80°C prior to analysis.  Samples were then 
transported from Aberdeen to Dundee for processing. Upon arrival the sample had thawed 
and were suspended in phosphate buffer saline where genomic DNA was extracted and 
purified using the DNA/RNA All Prep kit
14
 (Qiagen) and stored according to manufacturer’s 
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instructions. Standard protocol, 16S Metagenomic Sequencing Library Preparation Guide 
(Illumina), was followed to prepare sequencing libraries targeting the variable V3 and V4 
regions of the 16S rRNA gene and paired-end sequencing was performed on the MiSeq 
System (Illumina). We followed sampling and controls procedures described by the Earlham 
Institute 
(http://www.earlham.ac.uk/sites/default/files/docs/Genomic%20Services/Sample%20Guide
lines%20Aug17.pdf) and Illumina 
(https://support.illumina.com/documents/documentation/chemistry_documentation/16s/1
6s-metagenomic-library-prep-guide-15044223-b.pdf 
which are designed to minimize the risk for contamination.  Quality controls and sequencing 
were performed at Earlham Institute (Norwich, UK).  
Data and Statistical analysis  
Bioinformatics analyses on raw data was performed using the Biomedical Genomics 
Workbench version 4.0 (Qiagen) equipped with the Microbial Genomics Module version 2.0 
(Qiagen) plugin. Sequences were imported and processed for optional merge paired reads, 
adapter trimming, fixed length trimming and then the sequences were filtered based on the 
number of reads to obtain sequences that are comparable in length and coverage for 
clustering. Quality and chimera filtering were performed using the recommended 
programme parameters [for complete details see www.qiagenbioinformatics.com]. Samples 
with low coverage were removed from further analysis. Operational Taxonomic Units (OTU) 
clustering and taxonomic assignment were done using Greengenes v13_5 (97%) as 
reference. New OTUs were indicated when similarity percentage was lower than 80% with 
minimum occurrence of 5 reads. Low abundant OTUs were discarded from further analyses 
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(minimum combined abundance was set at 10). Summary of processed sequence data is 
described in Table S1.  MUSCLE was used for OTUs alignment in order to reconstruct a 
maximum likelihood phylogeny with neighbor joining as construction method and Jukes 
Cantor as nucleotide substitution model. We compared community structures and diversity 
across patient cohorts to determine if inter-cohort differences in structure were seen. To 
achieve this a rarefaction sampling analysis was carried out using a standard methodology
15
. 
In order to minimise the risk for contamination, we sought to identify a high (i.e. 
conservative) number of sequences required to characterise bacteria from the samples was 
determined from rarefaction.  In the absence of a standard international stringency cut off 
the default settings in the workbench software (Qiagen) were applied; the default settings 
filters out many reads and generates fewer unassigned reads and is therefore highly 
stringent. These adjustments were assessed by analyzing a previously characterized mock 
community to confirm that the data handling was consistent with other studies (sequencing 
files of the project: 
ERP021973,https://www.ebi.ac.uk/metagenomics/projects/ERP021973/samples/ERS15889
32). Data generated in the study was assessed using the Qiagen software and also applied to 
EBI Metagenomics analysis pipeline V3.0 to verify results (acknowledging that fewer reads 
would remain in the analysis with Qiagen).    The findings in the controls were taken into 
account during the analysis.   Alpha diversity was calculated using number of OTUs. Beta 
diversity was obtained using D_0.5 UniFrac and represented as Principal Coordinate Analysis 
(PCoA). Robustness analysis was performed using PERMANOVA with UniFrac distances. All 
sequencing data have been deposited in NCBI Sequence Read Archive (SRA) database under 
the follow BioProject ID:  PRJNA388557 
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RESULTS 
Study Subjects 
Twenty patients recruited of which 8 were boys, 7 with diagnosed asthma and the mean 
(standard deviation) age was 10.7 (2.8) years. Descriptives of the children recruited are 
given in Ttable 1.  Induced sputum was obtained from 12 children and samples of fluid from 
bronchus, throat mouth and nose were obtained in all children.  Three control samples were 
collected.   
Sample quality control 
A total of 11,750,879 PCR reads were were analysed, and 606,227 high quality reads were 
obtained.  The resulting OTU table contained 1053 OTUs, where 532 OTUs were assigned 
based on the Greengenes v13_5 (clustered at 97% similarity), and 521 OTUs were novel (see 
Table S1).  These processing criteria allowed data from 74 samples from patients for further 
analyses.  Of these 15 were from the nose, 16 from mouth, 17 from throat, 12 from sputum 
and 14 from bronchial samples (Table S2).  Samples from all five sites were available in six 
children. The median read counts for the five sites were as follows: bronchus 4438; mouth 
4400; throat 4868; nose 8927; and sputum 11250.  The results from the mock community 
analysis using Qiagen and EBI Metagenomics analysis pipelines were highly consistent.  
However Qiagen software assigned phyla for all samples whereas the EBI Metagenomics did 
not assign phyla in 15% of samples (see Table S3).    
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Bacterial abundance 
The relative bacterial abundance in each sample cohort is presented in Figure. 1. The overall 
profile of bacterial communities was largely similar in the mouth, throat and sputum 
samples with the nose and bronchial being different. All sample cohorts contained five 
major bacterial phyla: Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria and 
Proteobacteria. The three most abundant phyla of bacteria observed by analysis in nose, 
mouth, throat, bronchial and sputum were Actinobacteria, Fusobacteria and Bacteroidetes 
(seen in Figure 1).  Actinobacteria dominated in the nose (73% of all total species) and 
mouth (37%) samples, Fusobacteria dominated in throat (31%) and sputum (38%) samples 
and Proteobacteria were dominant in bronchial samples (34%).  Both nasal and bronchial 
samples had more unclassified OTUs (12% and 41% respectively) than other samples. The 
relative abundance of each individual sample is shown in Figure 2.  Figure S1 presents the 
phylogenetic tree of the microbial community in all analysed samples. In two of the control 
samples there was no identifiable bacteria DNA signal however some DNA signal was 
detected in the one of the three control and this was taken into account during analysis (See 
Figure 2).    
Comparison between complete community structures within samples from different sites 
The rarefaction analysis suggested that 2000 sequences would be sufficient for 
characterizing the majority of bacteria present in these communities. The numbers of reads 
were lowest in bacterial communities from mouth and bronchus (Figure 3; Table S2). A 
comparison of individual bacterial communities, using PERMANOVA principal coordinate 
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analysis (PCoA), showed a distinct clustering by sample cohorts based roughly on where the 
sample was taken from. Bacterial communities in samples from the mouth, throat and 
induced sputum were tightly clustered together (padj=1) and were distinct from those of 
the nose and bronchus (padj<0.001), which independently clustered (Figure 4; Table 2); 
these clustering results were seen when children with asthma and without asthma were 
considered separately (Table S4), Table S53 demonstrates that clustering of bacterial 
communities was not evident between sites among subgroups stratified by asthma/not 
asthma or atopy/not atopy. 
The bacterial communities in the five sites sampled did not differ between the children with 
and without asthma; there was evidence of some differences in bacterial abundance and 
diversity between groups (see supplement Figure S2). A comparison of the abundant phyla 
of bacteria identified in bronchial samples taken from asthma and non-asthma patients 
showed the profiles were similar, but the abundance of a signal for phyla was different (but 
did not reach significance).  In bronchial samples from asthma patients, the abundant phyla 
identified was Proteobacteria while those samples taken from non-asthma patients showed 
a greater abundance for Fusobacteria.   
 
DISCUSSION 
This study was designed to determine whether induced sputum is a valid alternative to 
directly sampling of the lower airways to study airway microbiota in children.  The main 
finding was that the characteristics of the microbiota in induced sputum and in bronchial 
samples were different.  A second finding was that a minority of bacterial DNA in bronchial 
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samples was unclassified.  In two individuals (P12 and P16, see Figure 2) the proportion of 
phyla identified from the bronchial sample was similar to the sputum sample but for the 
remainder of participants there were clear differences in the proportions of different phyla 
from bronchial and sputum samples. Together these findings suggest that induced sputum is 
not a valid surrogate for direct bronchial sampling to study the lower airway microbiota in 
all children, but that there is still a pressing need to better understand the lower airway 
microbiota in children.  Opportunistic bronchial sampling under clinically-indicated general 
anaesthetic will be requiredshould remain the gold standard for studying lower airway 
microbiome in children.  
To our knowledge there are only threewo studies which describe have compared the 
microbiota of upper and lower airway secretions in healthy children or children with 
asthma
6–8
.  A study where the majority of recruits were adults showed that the bacterial 
community in the oropharynx and bronchus were similar in healthy individuals
6
.   whereas 
One a solely paediatric study found very little overlap between the microbiota of the 
oropharynx and lower airways
7
 whilst a second paediatric study found similar predominant 
phyla in upper and lower airway samples but different genera8.  Both paediatric studies 
found significant differences in the clustering of bacterial communities in the upper and 
lower airways
7,8
. The difference indominant  phyla in between bronchial and throat samples 
is not consistent between studies but there is consistency for upper airway 
samplespreviously described
6,7
.  For example, the microbiota of the upper airways is 
predominated by bacteria from the Firmicutes (e.g. Staphylcoccus and Streptococcus) and 
the Actinobacteria phyla (e.g. Corynebacteria) in our study  and three others 
6–8
.  In contrast 
and in bronchial samples, bacterial species within the Proteobacteria phylum (including 
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Moraxella and Haemophilus) predominated in bronchial samples in our study and one 
other
7
 but Firmicutes dominated in a third study8., and especially in children with asthma
6
, 
whereas Differences in lower airway microbiome between studies may be due to different 
sampling methods8 and treatment with current or recent antibiotics
7,8
. in the microbiota of 
the upper airways is predominated by bacteria from the Firmicutes
6,7
 (e.g. Staphylcoccus 
and Streptococcus) and the Actinobacteria phyla
6,7
 (e.g. Corynebacteria). Our results, where 
we find no differences between the microbiome of induced sputum and throat swab,  are 
also consistent with previous studies which suggested that a throat swab may be a useful 
surrogate of induced sputum in young children with CF
9,10
. As our study did not include 
children with CF we cannot comment on the validity of induced sputum as an index of lower 
airway infection in this specific clinical setting.  The consistency of our results with previous 
studies assures us that our findings are valid, despite the relatively small sample size. 
Our study findings were based on samples taken from a group of children who were well.  
Recent work has given insight into the relationship between airway microbiota in the upper 
airways of children with acute infection, with results which differ from the present study.  
For example there is evidence that in the context of acute upper and lower respiratory tract 
infection, different bacterial species predominate in the nasopharynx (e.g. Proteobacteria 
and Firmicutes which contrast with Actinobacteria and Fusobacteria in our study)
15
. The 
characteristics of the nasopharyngeal microbiota also change during the course of acute 
otitis media infection
16
.     
Our study design minimised the risk of false positive results arising from contamination and 
from samples containing low DNA yields.  There is no consensus on the number of control 
samples which should be collected for microbiome studies, and two of the three controls we 
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collected contained no bacterial DNA and a third contained only bacteria with a very 
different profile of phyla compared to the samples from study subjects.  We set out to have 
a high threshold for reads (>2000) and this filtered out samples with low DNA yields.  
Another source of potential contamination comes from reagents used to analyse the 
samples and this risk was minimised by taking standard precautions were taken and by 
including control samples in the analysis.  Whilst we cannot exclude the possibility that 
some contamination may have occurred, our robust methodology and the consistency of 
our findings with previous studies assure us that any contamination has not substantially 
affected our findings. 
Finding a small proportion of unassigned bacterial DNA in the nose and bronchial samples 
was unexpected and worthy of further investigation.  The presence of “unclassified 
bacteria” has been described in nasopharyngeal samples from children
7
, but not in bronchial 
samples.  We have carefully reviewed the unassigned sequences and removed human DNA 
sequences, and we therefore believe that there are a number of bacteria in the respiratory 
tract which are not identified by standard microbiota methodologies currently used.    
We analysed data from a mock community (a “positive control”) and this demonstrated that 
the Qiagen software used for analysis of our samples was able to detect bacteria in similar 
proportions to another software “pipeline”. The Qiagen software identified all phyla 
whereas the alternative software could not assign 15% of bacterial DNA and this may be 
explained by the higher stringency set for the Qiagen software. There is not standard for 
stringency but these results suggest that although the higher stringency reduces the number 
of reads included in the analysis, the results are highly comparable to other methods and 
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possibly less affected by potential contaminants.  Our data are publicly available and 
colleagues are welcome to apply different stringencies to our data.   
There are a number of settings where upper airway samples have been shown to be valid 
surrogates of lower airway samples for the clinical diagnosis of infective and non-infective 
conditions.  Viral aetiology in bronchiolitis (a lower respiratory tract infection) can be 
established by nasopharyngeal aspirate
16
 and the nasal mucosa is used for diagnosis of 
primary ciliary dyskinesia
17
 and (in some situations) CF
18
.   In the research setting, sampling 
from the upper airways has been validated as a surrogate for lower airway sampling
19,20
.  
However, we demonstrated that the microbiota of the nose was distinct to mouth and 
bronchus in most individuals and our results indicating that the microbiota of the upper 
airway is probably not a valid surrogate of lower airway microbiota in children.  , and 
Previous papers have suggested that with regards to lower airway samples, upper airway 
samples are “imperfect but reliable”
7
 and “both similar and different”
8
and overall, our work 
finds more evidence for the upper airways samples being “imperfect and different” to lower 
airway samples and not “reliable and similar”. has been shown by other as well. 
The novelty of our study is that we demonstrate how the microbiota of induced sputum 
differs from bronchial samples and very closely matches the microbiota of mouth and 
throat, most likely due to contamination of lower airway secretions as they pass through the 
oropharynx, including sputum which is commonly mixed with expectorant.   Our findings are 
consistent with a study of 78 children (mean age 2 years, almost half having received recent 
antibiotic treatment) which also describes differences in the microbiota between nose and 
mouth and between mouth and bronchial fluid
7
.  Consistent with our findings, a study of 
adults and children (mean age 11 years) reports Actinobacteria being the predominant 
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phyla in the nose but being almost absent from the oropharynx and bronchus. A different 
pattern is shown for Proteobacteria which are increasing from nose through to oropharynx 
and bronchus
6
.  The apparent presence of different dominant bacterial communities in the 
upper and lower airways raises the question “where do bacteria in the lower airways 
originate?” 
In children the lower airways are in direct communication with and adjacent to the 
oropharynx but there are several  mechanisms that  may lead to the establishment of 
different bacterial communities above and below the vocal cords.  Perhaps most obviously, 
a child’s mouth is regularly exposed to food and inedible items introduced to the oral cavity 
(including cutlery and fingers) whereas the lower airways are exposed only to inhaled 
exposures.  Micro aspiration due to laryngopharyngeal reflux is thought to occur on a 
regular basis
21
 and exposure to acid and other gastric contents (including bacteria) may 
affect the microbiota of the lower airways but not the oropharynx. There are differences in 
the innate defences of the upper and lower airways which may also explain differences in 
their respective microbiota, for example lactoferrin concentrations are twice as high in the 
lower airways relative to upper airways
22
 whereas nitric oxide concentrations (known to 
have antimicrobial properties
23
) are typically one hundred times higher in the upper 
airways. 
Our study was not designed to relate microbiota to clinical phenotypic data collected, for 
example asthma or atopy. However, in light of recent studies examining these parameters in 
children with asthma
6,7
 we made the best use of the data available, even with the limited 
number we had at our disposal.  When examined the possible relationship between the 
bacteria present in children with and without asthma or atopy, we found no statistically 
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differences between the bacteria when the samples were examined as a whole group or as 
specific sample region cohorts (nose, mouth, throat, bronchial and sputum samples), Figure 
S2 and Table S3.  A descriptive analysis of the bronchial samples collected found 
Protoebacteria to be the dominant species and this is consistent with Hilty et al
6
.  
 
 
There are some limitations to our study.  First, the number of participants was relatively 
small.  Second, induced sputum was not obtained in all participants and not all samples met 
our quality control criteria for bacterial DNA analysis and this resulted in missing data for 
some individuals.  Third, as has been reported in other sputum microbiome studies
6,7
, we 
were not able to perform cell counts on the sputum pellet to determine the presence of 
neutrophils and absence of squamous epithelial cells. Finally, we did not prospectively 
calculate the DNA yield from samples although the consistency of our results with the small 
number of published studies
6,7
, the consistency of results using both the Qiagen and EBI 
Metagenomics pipelines and the comparable results from mock communities assure is that 
low DNA yield has not altered the results. although we included control samples in our 
methodology we did not include samples from commercially available “mock” communities.    
In summary, we report that neither induced sputum nor swabs from nose or mouth give an 
accurate indication of the bronchial microbiota in all children.  For very obvious practical 
and ethical reasons, upper airway sampling will be necessary to study airway microbiome in 
many research setting and our findings adds to the evidence describing the limitations of 
this pragmatic approach.    Our study was not designed to compare differences in the lower 
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airway microbiota of children with and without asthma, and future research is required to 
supplement the little we do know about this potentially important subject.  
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FIGURE LEGENDS 
Figure 1. Relative abundances of bacterial phyla identified as operational taxonomic units 
(OTUs) from the sequence reads generated from airway samples taken from children. The 
bar chart illustrates the taxonomic composition of each cohort of samples from a particular 
site. A detailed summary of the bacteria in each sample is described in Figure 2S1.  
Figure 2.  Operational Taxonomic Units based relative sequence abundance of bacterial 
phyla based on 16S rRNA of all 75 samples. A detailed summary of the bacteria in each 
sample is described. On the horizontal axis, the number following P is the patient number 
and NO=nose, MO=mouth, TH=throat, SP=Sputum, BR=bronchial sample. C2=the control 
sample where bacterial DNA was detected. N/A=not applicable 
Figure 3. Alpha diversity rarefaction curves of samples based on total number of observed 
Operational Taxonomic Units.  Colour denotes different sample cohort (“nose” (NO), 
“mouth” (MO), “throat” (TH), “sputum” (SP) and “bronchial” (BR) samples). 
Figure 4. Diversity analysis demonstrating differences in the bacterial phyla community 
between samples taken from airway samples taken from asthmatic and non-asthmatic 
children.  Principal coordinate (PCo) analysis of all samples based on D_0.5 UniFrac distance. 
Colour denotes different sample cohort (“nose” (NO), “mouth” (MO), “throat” (TH), 
“sputum” (SP) and “bronchial” (BR) samples). 
Figure S1. Phylogenetic tree of the microbial community in all analysed samples.  All 
Operational Taxonomic Units are shown in this figure. 
Figure S2.  Bacterial phyla abundance and diversity between groups. On the horizontal axis, 
the first letter “Y” indicates that the child had asthma and “N” that they did not have 
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asthma and NO=nose, MO=mouth, TH=throat, SP=Sputum, BR=bronchial sample. N/A=not 
applicable 
TABLE LEGENDS 
Table 1.  Details of the children recruited. SABA=short acting beta agonist, ICS=inhaled 
corticosteroids, LABA=long acting beta agonist 
Table 2.  PERMANOVA analysis results of testing differences in beta-diversity among 
different sample sites. 
Table S1. Summary of sequence data used for Operational Taxonomic Units (OTU) clustering 
and analysis.  The number of filtered reads and reads in OTUs doee not include the reads 
excluded by quality control 
Table S2.  List of sequence data for individual samples used for Operational Taxonomic Units 
(OTU) clustering and analysis. 
Table S3.  Comparison of results from two pipelines used to analyse data.  The Qiagen 
pipeline was used for the present study.  The EBA pipeline (full name EBI Metagenomics 
analysis pipeline V3.0) was used as a comparator 
Table S4. PERMANOVA analysis separately comparing beta-diversity among different sample 
sets for children with asthma and without asthma. 
Table S5Table S3. PERMANOVA analysis comparing beta-diversity among different sample 
sets. Atopy was defined as serum IgE >100 kU/l. 
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Whereas some minor issues have been addressed major issues are still not sufficiently replied to. I 
am still not convinced that one the main messages, namely that bronchial samples differ significantly 
from induced sputum, is justified by the data and therefore allows to conclude: “Induced sputum 
may not be a valid surrogate for microbiome assessment of the lower airways.”  
Before going into a deeper analysis I would like to mention that a considerable part of confusion 
comes due to erroneous labeling and numbering of the figures and tables. E.g. in my previous review 
I referred in point 4 to Fig. S2 which according to the legends was the phylogenetic tree (yet the 
Figure itself had no label) and claimed the absence of Streptococci and Haemophilus. In the reply the 
authors now refer to bar graphs that of course only show phyla. This is not a reply to my question. 
Moreover the current manuscript is still superficial in preparation: Fig. S2 as labeled in the legends 
(“Figure S2. Bacterial phyla abundance and diversity between groups”) is sjown as Fig. S3 on p.30. In 
Fig. 1 the legend gives a note “A detailed summary of the bacteria in each sample is described in 
Figure S1.” but this is now Fig. 2. Therefore I now always refer to the page number indicated at the 
top of the pdf file. 
 
Our response: We apologise for any confusion caused. On the advice of the reviewer we moved one 
figure from the supplement to the main paper.  Therefore the numbering of figures in the 
supplement changed between the first and the revised manuscript and we failed to capture all of 
these changes. There are four specific points raised by the reviewer here: 
1. Incorrect legend for Figure 1 - We have corrected the error in the legend for Figure 1 (i.e 
changed “Figure S1” to “Figure 2”). 
2. Reply to point 4 in initial review - The reviewer did not refer to Figure S2 in point 4 of their 
previous review (they did refer to this in point 7). We do not know which question the 
reviewer invites us to reply to.  
3. No label for phylogenetic tree in supplement - We have inserted a label for Figure S1. The 
Pediatric Pulmonology web site does not allow for a legend to be inserted separately (in 
contrast with figures for the main paper where a legend is inserted separately).  
4. Figure S2 labelled as Figure S3 - We have corr cted this error. 
 
Severe technical shortcomings remain and these are again outlined: 
1. It is not sufficiently clarified how the analysis results in such an enormous loss of reads: 
Previously of 21.5 million reads only 400,493 were analyses, now it reads that from 11.7 million reads 
606,227 could be analysed. Why were now fewer reads available? Why are less than 10% analysed? 
This is a very unusual yield for 16S sequencing. The authors refer to “high stringency” and p.7 for 
further explanations in their response but this stringency is nowhere explained. I am afraid that 
important information is missed. 
 
Our response: There are actually now more reads and a smaller proportion of “lost” reads included 
in the analysis reported in the revised manuscript (606,227 compared to 400,493). There is no 
standard for stringency and, as the reviewer will be aware, the advantage of a higher cut off reduces 
the potential for “false positive” findings. In this study, we used the default settings in the 
workbench software (Qiagen). This has a very “high stringency” cut off which means that a lot of 
reads are removed. Our data are publicly available and colleagues can apply different stringency 
thresholds to our data. We have expanded the text on page 7 to explain our approach to stringency 
which explains the threshold used. Finally (as suggested by the reviewer) we have used a mock 
community to replicate data from our pipeline using second pipeline which applied a different 
stringency; this last analysis indicates that our stringency has not affected the diversity of 
microbiome detected but has increased the accuracy of detection (data now included in Table S3). 
  
2. On “p.29 of 62” the authors again show the phylogenetic tree that should show “all analysed 
samples”. In this tree I do neither see the genus Streptococcus which should be found in all healthy 
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individuals at least in the mouth and throat or Haemophilus which has been reported as a typical 
proteobacterium in asthma patients. I come to the same conclusion as in (1.) that important 
information might be missing. That is why I requested to analyze a defined mock community but the 
authors refuse to do so. I do not see why this should not be possible even if the study was closed.  
 
Our response: This phylogenetic tree shows details of phyla and does not provide details of species. 
Therefore species such as Streptococcus and Haemophilus are not shown.  The analysis of mock 
community indicates that our pipeline more sensitive than a second pipeline and that important 
information is not missing. We have provided more labels on the phylogenetic tree identifying more 
phyla. 
 
 
3. I previously stated that I am afraid that in bronchial samples the bacterial yield might have 
been low and therefore prone to contamination. Indeed the new Fig. 2 clearly shows that in the one 
control sample proteobacteria were brought in. I am afraid that in samples with known low yield 
(bronchial washing from healthy individuals) this might induce an error as previously reported (Salter 
et al. BMC Biology 2014, 12:87). I therefore requested to do an analysis of bacterial load (e.g. 
quantitative 16S PCR). The authors now refer me to Table S2 but this is entirely misleading. “Number 
of reads” has nothing to do with the original bacterial load. During the pipeline of mixing and 
barcoding for the sequencing process typically equal amounts of PCR products are taken. After the 
sequencing the number of reads only reflects variation in the sequencing and does not relate to the 
original bacterial load. Without seeing true data on bacterial load the issue of contamination cannot 
be discussed in sufficient depth. 
 
Our response: We believe that the mock community analysis described previously addresses the 
issue of low DNA yield in bronchial samples (see Table S3). There was not sufficient sample volume 
to determine the bacterial yield. The mock community analysis and consistency with published data 
assure us that low bacterial load in bronchial samples has not substantially affected our results. We 
have added text acknowledging that we did not calculate DNA yield. We have also added a very 
recently published paper which also finds different clustering of bacterial communities in the upper 
and lower airways.  
 
4. From Table S2 it is visible that for the bronchial samples a number of samples had to be 
excluded because that did not give enough reads. I am afraid that the majority were from healthy 
children whereas those from asthmatic were analysed. The latter are known to have a higher 
Proteobacteria load. Therefore it is mandatory, to show the disease status in Fig. 2. Moreover, I 
would like to see separate PERMANOVAs for diseased and healthy children with respect to 
differences between sputa and bronchial washings. This is not covered so far by any of the analysis 
and from the Fig. on “p. 30 of 62” (mislabeled as S3) it becomes clear that the difference between 
NBR and NSP is much less as compared to YBR vs. YSP. I do NOT want to make a conclusion on 
asthma patients but I state that the mixing of healthy and diseased people in on population might be 
a significant problem. This might be also visible when Fig. 2 would be labeled with the disease status: 
From a look at Fig. 2 it seems that at least 3-4 samples are much more similar to the throat/sputum. 
The conclusion of difference between BR and SP is mostly based on the unassigned sequences and for 
those the data do not sufficiently exclude a contamination issue (see my comment 3). 
 
Our response: The reviewer makes a number of points here: 
• Samples need labelling by asthma status in figure 2. We have done this 
• Separate PERMANOVA for children with and without asthma.  We have done this (table S4) 
• Difference between BR and SP is mostly based on unassigned sequences.  We have now 
removed unassigned sequences from this figure and the majority of bronchial samples are 
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predominantly the light blue colour corresponding to Proteobacteriae whereas the sputum 
samples have very few Proteobacteriae seen but are dominated by Fusobacteria and 
Bacteroidites.  We do acknowledge that two bronchial samples (P12BR and P16 BR) have 
few Proteobacteriae and have a similar pattern to their corresponding sputum sample.  
When all patients are considered, there are significant differences between bronchial and 
sputum samples but we have modified the conclusions to acknowledge that in a minority 
sputum samples may be a valid index of bronchial samples.  
 
5. Technically it remains unclear why in Fig. 1 unassigned sequences are shown but in Fig. 2 
excluded. Moreover, on visual inspection there seems to be a discrepancy between proteobacteria 
abundance in Fig. 2 for all BR samples (for many samples >50%) as compared to Fig. 1 (20%). How 
has the data in Fig. 1 been calculated (mean?).  All in all the data do not sufficiently justify the main 
conclusion. 
 
Our response: We have revised Figure 1 and removed the unassigned phyla. The reviewer is correct 
and data in Figure 1 are mean values.  The proportion of proteobacteria in figure 2 is certainly >50% 
for most individuals but this figure shows how two individuals (P12BR and p16BR) have very few 
proteobacteria and results from these two individuals reduce the mean proportion of proteobacteria 
to the value represented in Figure 1. We have amended the main conclusion (see point 4 above). 
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